 WALTHAM, MA ACCESSWIRE November 7, 2019 EyeGate Pharmaceuticals, Inc. EYEG EyeGate or the Company, a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended September 30, 2019 and provided an update on recent corporate and operational activities. Stephen From, Chief Executive Officer of EyeGate, said, We are on track to receive topline results for the corneal wound healing pivotal study before the end of 2019 and continue to enroll for the follow-on pilot study in patients with punctate epitheliopathies PE. Completed enrollment of 250 patients for its corneal wound healing pivotal study in patients who have undergone photorefractive keratectomy PRK surgery. 